The Ministry of Finance has issued Notification No. 05/2024-Central Tax (Rate) dated 8th October 2024, amending the GST tax rates under the Central Goods and Services Tax (CGST) Act, 2017. Based on recommendations from the GST Council, the notification introduces changes across several product categories. Notably, three new pharmaceuticals—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—have been added to the 2.5% tax rate list. Snack products, specifically extruded or expanded savory or salted snacks, have been reclassified under both the 6% and 9% schedules, refining their tax applicability. Additionally, the tax rate on seats, including those used for motor vehicles, has been revised, with specific motor vehicle seats now listed under the 14% rate schedule. These amendments take effect from 10th October 2024. The notification continues a series of adjustments to the principal notification No. 1/2017-Central Tax (Rate), which initially established tax rates for various goods. The changes reflect the government’s ongoing efforts to refine GST structures based on industry developments and Council recommendations.
MINISTRY OF FINANCE
(Department of Revenue)
Notification No. 05/2024-Central Tax (Rate) | Dated: 8th October, 2024
— In exercise of the powers conferred by sub-section (1) of section 9 and sub-section (5) of section 15 of the Central Goods and Services Tax Act, 2017 (12 of 2017), the Central Government, on the recommendations of the Council, hereby makes the following further amendments in the notification of the Government of India, Ministry of Finance (Department of Revenue), notification No. 1/2017-Central Tax (Rate), dated the 28th June, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 673(E), dated the 28th June, 2017, namely:-
In the said notification, –
(a) after Schedule I – 2.5% , in List 1, after item number 232 and the entries relating thereto, the following item numbers and entries shall be inserted, namely: –
“(233) Trastuzumab Deruxtecan
(234) Osimertinib
(235) Durvalumab”;
(b) in Schedule II – 6%, after S. No. 32B and the entries relating thereto, the following S. No. and entries shall be inserted, namely: –
| “32C | 1905 | Extruded or expanded products, savoury or salted (other than un-fried or un-cooked |
| 90 30 | snack pellets, by whatever name called, manufactured through process of extrusion)”; |
(c) in Schedule III – 9%, –
(i) against S. No. 16, in column (3), for the words “un-fried or un-cooked snack pellets, by whatever name called, manufactured through process of extrusion”, the words “un-fried or un-cooked snack pellets, by whatever name called, manufactured through process of extrusion, extruded or expanded products, savoury or salted” shall be substituted;
(ii) for S. No. 435A and the entries relating thereto, the following S. No. and entries shall be substituted, namely: –
| “435A | 9401 [other than 9401 10 00 or 9401 20 00] | Seats (other than those of heading 9402), whether or not convertible into beds and parts thereof other than seats of a kind used in aircraft or seats of a kind used for motor vehicles”; |
(d) in Schedule IV – 14%, after S. No. 210 and the entries relating thereto, the following S. No. and entries shall be inserted, namely: –
| “210A | 9401 20 00 | Seats of a kind used for motor vehicles”. |
2. This notification shall come into force on the 10th day of October, 2024.
[F. No. CBIC-190354/149/2024-TO(TRU-II)]
AMREETA TITUS, Dy. Secy.
Note: – The principal notification No. 1/2017-Central Tax (Rate), dated the 28th June, 2017, was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R. 673(E), dated the 28th June, 2017, and was last amended vide notification No. 2/2024 – Central Tax (Rate), dated the 12th July, 2024, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R. 396(E), dated the 12th July, 2024.
